Literature DB >> 10971033

Bioartificial skin.

H G Machens1, A C Berger, P Mailaender.   

Abstract

The loss of skin has been one of the oldest, yet most frequent and costly problems in our health care system. To restore functional and esthetic integrity in patients with unstable or hypertrophic scars, in burn patients and after skin loss for hereditary, traumatic or oncological reasons, an armamentarium of reconstructive surgical procedures including autogenous, allogenous and xenogenous tissue transfer as well as implantation of alloplastic materials has been favored. For several decades there has been increasing interest focused on 'tissue engineering' of dermal, epidermal and full thickness skin substitutes by both biological and synthetic matrices. At our institution (Hannover Medical School), a collagen/glycosaminoglycan dermal regeneration matrix has been used for immediate dermal coverage after escharectomy in burn injuries as well as for dermal replacement in chronically unstable scars. This article gives an overview on the current state of the art in bioartificial skin as well as our personal experience with the collagen/glycosaminoglycan matrix for dermal replacement in different clinical situations. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971033     DOI: 10.1159/000016772

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  18 in total

1.  Gelatin-based anionic hydrogel as biocompatible substrate for human keratinocyte growth.

Authors:  Filippo Renò; Manuela Rizzi; Mario Cannas
Journal:  J Mater Sci Mater Med       Date:  2011-12-13       Impact factor: 3.896

Review 2.  [Regenerative medicine and plastic surgery].

Authors:  H-G Machens; P Mailänder
Journal:  Chirurg       Date:  2005-05       Impact factor: 0.955

Review 3.  Tissue engineering in head and neck reconstructive surgery: what type of tissue do we need?

Authors:  Ulrich Reinhart Goessler; Jens Stern-Straeter; Katrin Riedel; Gregor M Bran; Karl Hörmann; Frank Riedel
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-13       Impact factor: 2.503

4.  Vacuum-assisted closure improves the incorporation of artificial dermis in soft tissue defects: Terudermis(®) and Pelnac(®).

Authors:  SuRak Eo; YoongSoo Kim; SangHun Cho
Journal:  Int Wound J       Date:  2011-02-25       Impact factor: 3.315

Review 5.  New technologies in global burn care - a review of recent advances.

Authors:  Laura Kearney; Eamon C Francis; Anthony Jp Clover
Journal:  Int J Burns Trauma       Date:  2018-08-20

6.  Engineered pullulan-collagen composite dermal hydrogels improve early cutaneous wound healing.

Authors:  Victor W Wong; Kristine C Rustad; Michael G Galvez; Evgenios Neofytou; Evgenios Neofyotou; Jason P Glotzbach; Michael Januszyk; Melanie R Major; Michael Sorkin; Michael T Longaker; Jayakumar Rajadas; Geoffrey C Gurtner
Journal:  Tissue Eng Part A       Date:  2010-11-17       Impact factor: 3.845

7.  The use of dermal substitutes in burn surgery: acute phase.

Authors:  Shahriar Shahrokhi; Anna Arno; Marc G Jeschke
Journal:  Wound Repair Regen       Date:  2014 Jan-Feb       Impact factor: 3.617

Review 8.  Severe burn injuries: acute and long-term treatment.

Authors:  Timo A Spanholtz; Panagiotis Theodorou; Peymaneh Amini; Gerald Spilker
Journal:  Dtsch Arztebl Int       Date:  2009-09-18       Impact factor: 5.594

9.  Dermal regenerative matrix use in burn patients: A systematic review.

Authors:  Katie E Hicks; Minh Nq Huynh; Marc Jeschke; Claudia Malic
Journal:  J Plast Reconstr Aesthet Surg       Date:  2019-08-08       Impact factor: 2.740

Review 10.  Skin cancers and dermal substitutes: Is it safe? Review of the literature and presentation of a 2-stage surgical protocol for the treatment of non-melanoma skin cancers of the head in fragile patients.

Authors:  Marco Marcasciano; Marco Mazzocchi; Juste Kaciulyte; Noemi Spissu; Donato Casella; Diego Ribuffo; Luca Andrea Dessy
Journal:  Int Wound J       Date:  2018-06-04       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.